Safety & Efficacy of Prolonged Physiologic Erythropoietin (EPO) Level Treatment of Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Using MDGN201 TARGTEPO
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
Price : $35 *
At a glance
- Drugs MDGN 201 (Primary)
- Indications Anaemia
- Focus Pharmacokinetics; Proof of concept
- Sponsors Medgenics
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 21 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2016.
- 21 Apr 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2016.